Senseonics Posts -66.62% ROIC Versus 8.89% WACC, Trails Peer Efficiency
Senseonics’ WACC stands at 8.89% while ROIC is -66.62%, yielding a ROIC/WACC ratio of -7.50, indicating negative returns relative to cost of capital. The company outperforms Bionano and Zomedica but lags behind Castor Maritime’s less negative capital efficiency.
1. Core Financial Metrics
Senseonics reports a weighted average cost of capital (WACC) of 8.89% against a return on invested capital (ROIC) of -66.62%, resulting in a ROIC/WACC ratio of -7.50. This gap signifies the company is not generating returns sufficient to cover its capital costs, raising concerns about its current investment efficiency.
2. Peer Benchmarking
In a comparative analysis, Senseonics outperforms Bionano Genomics (ROIC/WACC -15.00) and Zomedica (ROIC/WACC -7.54) but remains behind Castor Maritime, which posts a ROIC/WACC ratio of -0.76. This positions Senseonics in the middle of its peer group regarding capital efficiency, although all peers fail to exceed their cost of capital.
3. Implications and Outlook
Negative ROIC relative to WACC suggests the company must either boost profitability or lower capital costs to enhance shareholder value. Strategic initiatives could include streamlining R&D expenditures, optimizing manufacturing costs of the Eversense CGM System, or securing more favorable financing terms to narrow the gap.